Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease

Not Applicable

• Conditions: Cardiac TTR Amyloidosis
• Interventions: Diagnostic Test: Tc99m-labeled pyrophosphate scan

• Registration Number: NCT03098901
• Lead Sponsor: Kaplan Medical Center

Brief Summary

Cardiac amyloidosis is a multi-organ syndrome, which usually presents as restrictive cardiomyopathy (RCM). Transthyretin (TTR) amyloidosis (or ATTR) is a subtype of amyloidosis which frequently involves heart. Cardiac ATTR, though infrequently diagnosed during lifetime, may represent a prevalent cause of RCM, especially in elderly. Several medications that can limit progression of the disease are currently under investigation. Presently the golden standard for diagnosis of ATTR is endomyocardial biopsy (EMB) which may entail severe adverse complications causing under-diagnosis of ATTR.

Several papers support the evidence that Tc99m-labeled tracers can be used to detect myocardial deposits of TTR amyloid. It was suggested that Tc99m scintigraphy might be a highly sensitive diagnostic tool for cardiac ATTR. In this study the patients with otherwise unexplained cardiomyopathy or heart block will undergo Tc99m scan, which will establish the incidence of this largely underdiagnosed condition in the population.

Detailed Description

Amyloidosis is a multi-organ syndrome, which usually presents as a restrictive cardiomyopathy (RCM). Transthyretin (TTR) amyloidosis is a subtype of amyloidosis, further subdivided into familial type and senile type. Its pathophysiology consists primarily of abnormal precipitation of transthyretin - a protein that normally acts as transporter for thyroid hormone and retinoids - in tissues. TTR amyloidosis frequently involves heart, bringing about the same clinical and pathophysiological picture of RCM. Another presentation of TTR Amyloidosis can be atrio-ventricular block or bundle-branch block \[1\].

There is evidence that the cardiac TTR amyloidosis, though infrequently diagnosed during the lifetime, may represent a widespread cause of restrictive cardiomyopathy especially in elderly. An autopsy study in octogenarians having suffered of heart failure with preserved left ventricular ejection fraction (HFpEF) suggested that up to 25% of them had TTR amyloid deposit in myocardium, though a negligible minority of them had been diagnosed with TTR amyloidosis during their lifetime \[2-3\]. HFpEF is a very widespread diagnosis, which represents a considerable burden of morbidity, and usually harbours populations of patients poorly responding to treatment. Most of patients with the diagnosis of HFpEF have little or no explanation concerning the aetiology of their disease, especially if they do not respond to conventional treatment. Most of them can benefit only from symptomatic treatment which does not alter the course of the disease. Thus a more widespread diagnosis of TTR amyloidosis could have been very promising as to a better management of this hard-to-treat patient population.

Several medications that can limit progression of TTR amyloidosis are currently under investigation. Until now, the golden standard for diagnosis of the disease was endomyocardial biopsy (EMB) which may entail several adverse complications and thus limit widespread diagnosis. Since amyloidosis is a multi-organ disease, extra-cardiac biopsy was proposed as a surrogate tissue diagnosis, though in TTR amyloidosis its sensitivity is below 50% \[4\].

Recently several papers support the evidence that Tc99m-labeled pyrophosphate (PYP) and bisphosphonates when injected intravenously localize to myocardial deposits of TTR amyloid. It was thus suggested that Tc99m scintigraphy might be a highly sensitive and specific diagnostic tool for cardiac TTR amyloidosis \[5-9\]. It was shown that almost the only source of false positive Tc99m scintigraphy is primary amyloidosis, which is a different entity, with worse prognosis, different treatment, although frequently involves heart as well \[10\]. Primary amyloidosis can be diagnosed by means of demonstration of monoclonal immunoglobulin peak in serum and immunoglobulin light chains in serum and urine \[11\]. Therefore, the specificity of Tc99m scan for TTR amyloidosis can be brought to an extraordinary level, with virtually negligible false positive rate, if primary amyloidosis is excluded prior to referral to Tc99m scan. The other entity where false positive uptake of Tc99m in myocardium can be observed is acute myocardial infarction. Currently the Tc99m-PYP scan is utilised as bone scan according to guidelines in order to diagnose wide spectrum of diseases such as stress fractures or metastatic bone disease.

At present the mentioned hypothesis that TTR amyloidosis might be a widespread cause of HFpEF has not been established in a clinical trial due to the fact that until now the most accurate diagnosis of TTR amyloidosis required an invasive procedure with possible adverse outcomes while the extra-cardiac biopsy had low diagnostic yield. Advent of a novel, possibly as accurate, yet non-invasive diagnostic tool opens new opportunities to set such study.

The incidence of both familial type and senile type TTR amyloidosis among patients with diagnosis of otherwise unexplained heart failure or heart block will be evaluated in this study by means of Tc99m scan using SPECT technology as described above. The hypothesis is that if the incidence of TTR amyloidosis within the population of patients suffering of HFpEF is as high as it was demonstrated by the autopsy studies, then we will be able to establish the diagnosis in a larger cohort of patients. This will make new developments in the research of the disease, such as treatment and outcome driven trials, possible.

Establishing the diagnosis of TTR amyloidosis in patients with HFpEF will improve our decision-making ability regarding the patients' treatment, for example preventing unnecessary invasive measures in patients with comorbidities demanding such measures, the alternative diagnoses being unrevealed.

Study Timeline

• Study First Submitted: 2017-03-28
• Study First Submitted QC: 2017-03-31
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-03
• Study First Posted: 2017-04-04
• Last Update Posted: 2017-04-05
• Study Start: 2017-04-15
• Primary Completion: 2018-04-15
• Study Completion: 2018-04-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Heart Failure with Preserved Ejection Fraction not explained by either hypertension or any other clinical condition.
2. Systolic dysfunction and non-significant coronary artery disease.
3. Diabetic cardiomyopathy
4. Otherwise unexplained left ventricular hypertrophy (LVH).
5. Under age of 65 and idiopathic ventricular fibrillation (VF) or multiple ventricular premature beats (VPB) or ventricular tachycardia (VT) with a structurally normal heart.
6. Under age of 65, and unexplained sinus node disease, sinoatrial block, complete or high-degree atrio-ventricular block or significant intraventricular conduction defect, with structurally normal heart whether having or not having received permanent implanted pacemaker.

Exclusion Criteria

1. Primary amyloidosis cannot be excluded,
2. Acute or recent (3 months) myocardial infarction,
3. Acute or recent (12 months) myocarditis,
4. Oncologic or any other co-morbidity, which can shorten the patient's survival to less than one year,
5. End stage renal disease treated with dialysis,
6. Ischemic cardiomyopathy,
7. Non-TTR amyloidosis known or suspected,
8. Another type of cardiomyopathy (for ex. arrhythmogenic right ventricular dysplasia),
9. Any disease or clinical condition that can lead to cardiomyopathy (history of anthracyclines treatment, history of alcohol abuse, multiple myeloma, sarcoidosis, carcinoid, inflammatory and autoimmune diseases).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
no other arm	Tc99m-labeled pyrophosphate scan	-

Primary Outcome Measures

Name	Time	Method
diagnosis or exclusion of any type of cardiac amyloidosis;	immediately at the Tc99m scan performing or within a year form beginning of the recruitment	diagnosis of cardiac TTR amyloidosis, or any other type of cardiac amyloidosis, or diagnosis of another condition other than amyloidosis explaining the patient's clinical cardiological findings